COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00190333
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : February 18, 2011
Information provided by:
Assistance Publique - Hôpitaux de Paris

Brief Summary:
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of escitalopram (30 mg/day) in two parallel groups (randomization ratio, escitalopram 2/placebo 1).

Condition or disease Intervention/treatment Phase
Pulmonary Hypertension Drug: escitalopram Phase 3

Detailed Description:
Primary objective: to evaluate the efficacy of oral escitalopram at the dosage of 30 mg/day for 16 weeks on the 6-minute walking test in patients with pulmonary hypertension.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of the Therapeutic Effects of Escitalopram in Pulmonary Hypertension, Either Primary or Associated
Study Start Date : June 2005
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: A Drug: escitalopram

Primary Outcome Measures :
  1. To evaluate the efficacy of oral escitalopram at the dosage of 30 mg/day on the 6-minute walking test in patients with pulmonary hypertension [ Time Frame: for 16 weeks ]

Secondary Outcome Measures :
  1. To evaluate the efficacy of escitalopram in improving hemodynamic parameters (right heart catheterization; decision of doing right heart catheterization belonging to the investigators) [ Time Frame: after 16 weeks ]
  2. To evaluate the efficacy of escitalopram in improving the New York Heart Association (NYHA) class [ Time Frame: after 16 weeks ]
  3. To evaluate the efficacy of escitalopram in improving the dyspnea (visual analog scale) [ Time Frame: after 16 weeks ]
  4. To evaluate the efficacy of escitalopram in improving the quality of life [ Time Frame: after 16 weeks ]
  5. To evaluate the efficacy of escitalopram in reducing exacerbations of signs or symptoms of the disease that would otherwise require hospital admission or treatment intensification, particularly treatment with bosentan or IV administration of epoprostenol [ Time Frame: after 16 weeks ]
  6. To evaluate the safety of escitalopram, alone or on top of associated drugs [ Time Frame: after 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects who meet all the criteria listed below will be considered for study inclusion:

  • Male or female older than 18 years of age
  • Meeting World Health Organization (WHO) criteria for pulmonary hypertension (mean pulmonary arterial pressure [PAP] > 25 mmHg at rest and pulmonary capillary wedge pressure < 15 mmHg during right heart catheterization):

    • primary pulmonary hypertension (sporadic or familial), or
    • pulmonary hypertension associated with connective tissue diseases, or
    • pulmonary hypertension associated with HIV infection, or
    • pulmonary hypertension associated with use of appetite suppressants or other toxic compounds, or
    • pulmonary hypertension associated with shunting through a congenital heart defect surgically treated
  • Class II or III in the NYHA classification scheme
  • With a 6-minute walking test distance between 40% and 80% of theoretical values (approximately 50 and 480 m)
  • On conventional treatment, with no change in this treatment during the last month preceding the study. Conventional treatment includes calcium antagonists or beraprost.
  • Subject who consents to participate in the study.

Exclusion Criteria:

Subjects with any of the following clinical features will not be included in the study:

  • Pulmonary hypertension related to aortic or mitral valve disease, or extrinsic pulmonary vein compression
  • Pulmonary hypertension related to hypoxia from respiratory disease with a total lung capacity < 70% or Tiffeneau index < 60% upon testing within the last 6 months (chronic obstructive lung disease, interstitial disease, sleep apnea syndrome, alveolar hypoventilation, chronic exposure to high altitudes, neonatal lung disease, or alveolar capillary dysplasia)
  • Pulmonary hypertension associated with portal hypertension
  • Pulmonary hypertension secondary to chronic thrombosis and/or embolism (occlusion of the proximal or distal pulmonary arteries by thrombosis)
  • In the 6-minute walking test, inability to walk for 6 minutes, for any reason, or walking distance of less than 50 m
  • Pregnancy, lactation, women of childbearing potential (if needed, effective contraception will be prescribed)
  • History of hypersensitivity to citalopram or to medications structurally related to citalopram
  • Treatment with another investigational drug within the 3 months preceding study inclusion
  • Cardiovascular, hepatic, neurological or endocrine disease that is clinically significant, or any other significant disease that may interfere with the study protocol or with the interpretation of study findings
  • History of drug or alcohol abuse
  • Liver failure (except abnormalities related to the right ventricular failure)
  • Kidney failure
  • Mental status preventing the patient from understanding the nature, objectives, and possible consequences of the study
  • Non stabilized psychiatric disorders
  • Subject unable to comply with protocol-related constraints (e.g., uncooperative, unable to attend follow-up visits, and probably unable to complete the study).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00190333

Layout table for location information
Louis Pradel Hospital
Bron, France, 69677
Antoine Beclere Hospital
Clamart, France, 92140
Henri Mondor Hospital
Creteil, France, 94010
Michallon Hospital
Grenoble, France, 38043
Sainte Marguerite Hospital
Marseille, France, 13009
Haut Lévèque Hospital
Pessac, France, 33604
Hautepierre Hospital
Strasbourg, France, 67200
Rangueil Hospital
Toulouse, France, 31059
Brabois Hospital
Vandoeuvre les Nancy, France, 54500
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Layout table for investigator information
Study Chair: Gerald SIMONNEAU, MD Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Isabelle BRINDEL, Department of Clinical Research of developpement Identifier: NCT00190333    
Other Study ID Numbers: P020305
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: February 18, 2011
Last Verified: March 2007
Keywords provided by Assistance Publique - Hôpitaux de Paris:
pulmonary hypertension
6 minutes walking test
primary or associated pulmonary hypertension
Additional relevant MeSH terms:
Layout table for MeSH terms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Serotonin Agents
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs